TrialEuropean journal of cancer (Oxford, England : 1990)2015

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.

Maha Hussain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.